Reuters logo
BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients
November 9, 2017 / 12:07 PM / a month ago

BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients

Nov 9 (Reuters) - Merck & Co Inc

* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients

* Merck & Co Inc - ‍Prevymis is expected to be available in december​

* Merck & Co Inc - ‍list price (wholesaler acquisition cost) per day for Prevymis tablets is $195.00 and for Prevymis injection is $270.00​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below